Every week we pull one stock from the Wall Street Favorites rankings and break down exactly what Wall Street is expecting.
This week: Boston Scientific (BSX) — the medical device maker behind Watchman, cardiac ablation, and one of the largest electrophysiology franchises in healthcare.
The stock is down -59% from its 52-week high and -53% YTD after management cut full-year guidance. But WSF's valuation model now reads it as undervalued across all three metrics, and Wall Street still sees +52% upside. It also reports earnings tomorrow morning.
🎯 Key Metrics & Analyst Targets
P/E: 18.6x — vs 10-year average of 59.2x
P/Sales: 3.2x — vs 10-year average of 5.0x
P/OCF: 15.3x — vs 10-year average of 34.5x
Wall Street’s Rating: Mixed: Wolfe Research → Peer Perform, Wells Fargo → Equal Weight, Raymond James → Outperform
Wall Street’s Price Target: $68 — implying +52.3% upside from $44.65
Most Bullish Target: $89 — Barclays, Overweight
🔮 Wall Street’s Forward Earnings Expectations (2027)
Revenue: $23.3B (+8.1%)
Net Income: $5.5B (+9%)
EPS: $3.7 (+10.5%)
Operating Cash Flow: $5.4B (+7.8%)
Free Cash Flow: $4B (-2.6%)
🏦 Institutional & Hedge Fund Activity
Institutional Investors: 1,718
Positions Opened: +195
Positions Closed: -338
Holder Growth: -7% QoQ
Wall Street Favorites provides stock rankings for informational purposes only. This is not investment advice. All data sourced from public filings, analyst reports, and WSF proprietary scoring. Past rankings do not guarantee future results. Investing involves risk including possible loss of principal.